FoundationOne CDx
FDA premarket approval P170019/S044 · decided 2023-05-26
Approval details
- PMA number
- P170019
- Supplement
- S044
- Supplement type
- Normal 180 Day Track No User Fee
- Supplement reason
- Postapproval Study Protocol
- Trade name
- FoundationOne CDx
- Generic name
- Next generation sequencing oncology panel, somatic or germline variant detection system
- Applicant
- Foundation Medicine, Inc.
- Date received
- 2023-05-12
- Decision date
- 2023-05-26
- Days to decision
- 14 days
- Decision code
- APPR
- Product code
- PQP
- Advisory committee
- Pathology
- Expedited review
- No
- Location
- Boston, MA
- Statement
- Approval of the clinical protocol entitled Statistical Analysis Plan for F1CDx Clinical Bridging Study of Entrectinib Efficacy for NTRK
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.